Matti Lehtinen

Scientific approaches to defining <scp>HPV</scp> vaccine‐induced protective immunity

Evaluation of an HPV16-L1 antibody rapid test for oropharyngeal cancer diagnosis: diagnostic accuracy and challenges in real-world settings

Scientific approaches toward improving cervical cancer elimination strategies

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study

Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts

<scp>HPV16 E6</scp>‐antibody associated risk of oropharyngeal cancer increases by calendar‐time: A nested case‐control study

Assessing the risk of cervical neoplasia in the <scp>post‐HPV</scp> vaccination era

Association of Helicobacter pylori and Autoimmune Gastritis With Stomach Cancer in a Cohort of Young Finnish Women

Elevated risk of HPV-associated oropharyngeal cancers in husbands of women with anogenital cancer appears calendar-time dependent

Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial

Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial

Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial

Impact of HPV vaccination on cervical screening performance: a population-based cohort study

Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied

Human Papillomavirus Genotype Replacement: Still Too Early to Tell?

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort

Long‐term follow‐up of human papillomavirus type replacement among young pregnant Finnish females before and after a community‐randomised <scp>HPV</scp> vaccination trial with moderate coverage

Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women

Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial

Population-Based Human Papillomavirus Serosurvey Reveals HPV16/18 Herd Effect But No Clear Type-Replacement in Unvaccinated Females 6 Years Post Gender-Neutral Vaccination in a Cluster Randomised Trial

Moderate Coverage Vaccination Eradicates Oncogenic Human Papillomaviruses if a Gender-Neutral Strategy is Applied

Vaccination protects against invasive HPV‐associated cancers

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of <i>three cohorts from randomized trials</i>

Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium

Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study